Results 291 to 300 of about 412,750 (330)

Clinical Importance of Phosphodiesterase 3 Inhibitors on Outcomes in Patients With Cardiogenic Shock - A Systematic Review. [PDF]

open access: yesCirc Rep
Yamamoto M   +22 more
europepmc   +1 more source

Increased calcification by erythrophagocytosis in aortic valvular interstitial cells

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1469-1473, April 2025.
Abstract Background Calcific aortic valve disease (CAVD) progresses over time to severe aortic stenosis and eventually heart failure. Recent evidence indicates that intraleaflet haemorrhage (ILH) strongly promotes CAVD progression. However, it remains poorly understood how it mechanistically contributes to valvular calcification.
Zihan Qin   +3 more
wiley   +1 more source

Safety and Efficacy of Intravenous Magnesium for Torsade de Pointes - A Scoping Review. [PDF]

open access: yesCirc Rep
Sangawa M   +16 more
europepmc   +1 more source

Digital health in cardiovascular medicine: An overview of key applications and clinical impact by the Portuguese Society of Cardiology Study Group on Digital Health

open access: diamond
M Grine   +6 more
openalex   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger   +15 more
wiley   +1 more source

Editorial: The right heart: a key target for cardiovascular medicine. [PDF]

open access: yesFront Cardiovasc Med
Pastore MC   +3 more
europepmc   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul   +13 more
wiley   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi   +3 more
wiley   +1 more source

Editors' message - September 2025. [PDF]

open access: yesAm J Prev Cardiol
Wong ND, Michos ED.
europepmc   +1 more source

Home - About - Disclaimer - Privacy